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John van der Oost1 and Richard van Kranenburg1,3
High engineering efficiencies are required for industrial strain
development. Due to its user-friendliness and its stringency,
CRISPR-Cas-based technologies have strongly increased
genome engineering efficiencies in bacteria. This has enabled
more rapid metabolic engineering of both the model host
Escherichia coli and non-model organisms like Clostridia,
Bacilli, Streptomycetes and cyanobacteria, opening new
possibilities to use these organisms as improved cell factories.
The discovery of novel Cas9-like systems from diverse
microbial environments will extend the repertoire of
applications and broaden the range of organisms in which it
can be used to create novel production hosts. This review
analyses the current status of prokaryotic metabolic
engineering towards the production of biotechnologically
relevant products, based on the exploitation of different
CRISPR-related DNA/RNA endonuclease variants.
Addresses
1 Laboratory of Microbiology, Wageningen University, Stippeneng 4,
6708 WE Wageningen, The Netherlands
2 The Novo Nordisk Foundation Center for Biosustainability, Technical
University of Denmark, Kemitorvet B220, 2800 Kgs. Lyngby, Denmark
3Corbion, Arkelsedijk 46, 4206 AC Gorinchem, The Netherlands
Corresponding author: van Kranenburg, Richard (richard.
vankranenburg@wur.nl)
4 These authors contributed equally to this work.
Current Opinion in Biotechnology 2018, 50:146–157
This review comes from a themed issue on Environmental
biotechnology
Edited by Mike Jetten and Irene Sa´nchez Andrea
https://doi.org/10.1016/j.copbio.2018.01.002
0958-1669/ã 2018 The Authors. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
Introduction
The transition towards a bio-based economy demands the
development of fermentation-based processes economi-
cally competitive with the currently employed unsustain-
able production processes [1]. Unfortunately, only very
few natural organisms are suitable for their direct appli-
cation in an industrial process. Therefore, efficient meta-
bolic engineering via targeted genome engineering is
required and the development and use of simple and
high-throughput genome engineering tools generally
applicable to many model and non-model organisms is
of great importance [2].
Most prokaryotes possess homology directed repair
(HDR) systems, which have since long been exploited
in a great variety of microorganisms for targeted chromo-
somal integrations of desired modifications [3–5]. In the
HDR-based systems, plasmid-borne homologous recom-
bination templates, which often harbor selection markers
for screening purposes, are introduced into the genome
through double or sequential single crossover events.
The HDR-based approach is usually combined with
additional systems, such as the site-specific resolvase
based Cre-lox or FLP-FRT systems, for excision of the
markers from the genomes for recycling purposes. How-
ever, these systems leave genomic scars that could be the
cause of unwanted chromosomal rearrangements [6,7].
Alternatively, for a small number of bacteria, markerless
genomic modifications are possible via recombineering
systems [8]. These systems are based on bacteriophage
recombinases and ssDNA, dsDNA or plasmid-borne
DNA fragments with sequence homology to the genomic
target. However, due to the absence of marker-based
selection, these systems mostly result in low mutation
efficiencies [8]. The construction and screening of
mutants in all these HDR-based approaches is time
consuming, rendering these tools suboptimal for exten-
sive metabolic engineering, particularly in non-model
organisms with low transformability and recombination
rates.
A breakthrough  moment in the molecular microbiology
field was the discovery of bacterial adaptive immune
systems that are based on genomic Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPRs)—
the memory of the systems—and CRISPR-associated
(Cas) proteins [9–11]. The repurposing of the RNA-
guided DNA endonuclease from the type IIa CRISPR-
Cas system of Streptococcus pyogenes (spCas9) and of other
Cas9 orthologues as genome editing tools brought an
unprecedented revolution to the life sciences field
[2,12,13]. The basis of the Cas9 engineering tools is
the simple way in which Cas9 nucleases can be guided
to the desired DNA target, denoted as protospacer, by a
CRISPR–RNA:trans-activating CRISPR RNA (crRNA:
tracrRNA) hybrid complex. For this purpose, the 50-end
of the crRNA module, denoted as spacer, has to be
complementary to the selected protospacer [14] and a
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specific short DNA motif, denoted as protospacer adja-
cent motif (PAM), has to be present at the 30-end of the
selected protospacer [15,16]. For further simplification
of the engineering processes, the crRNA:tracrRNA com-
plex can be combined into a chimeric single guide RNA
(sgRNA) [17].
CRISPR-Cas-based genome editing is now broadly
used in a variety of organisms, including human cells,
zebrafish, plants, yeast and bacteria [18,19]. The suc-
cessful application of Cas9-based genome editing in
eukaryotic cells is based on the error-prone correction
of Cas9-induced double-strand DNA breaks (DSBs) by
the efficient eukaryotic Non-Homologous End Joining
(NHEJ) mechanism. Contrary to eukaryotes, most pro-
karyotes do not have an active NHEJ system [3] and
Cas9-induced DSBs cannot be repaired, resulting in
cell death. Recent studies have shown that engineer-
ing efficiencies in prokaryotes were strongly increased
(often up to 100%) upon combining the existing
homologous recombination and recombineering systems
with Cas9-targeting; the Cas9-induced DNA breaks
served, simultaneously, as recombination inducers and
counter-selection tools [12,20,21]. Moreover, catalyti-
cally inactive variants of Cas9 orthologues and variants
fused with transcriptional activating factors have been
developed and used for transcriptional regulation. Alto-
gether, CRISPR-Cas9 orthologues and catalytically
inactive mutants have accelerated the construction
and screening of in silico designed strains, facilitating
metabolic engineering of a wide range of bacterial
species for industrial cell factory development
(Figure 1).
In this review, we summarize recent bacterial metabolic
engineering studies that focused on the construction and
improvement of microbial cell factories, making use of
CRISPR-Cas-based technologies. Additionally, we
explore newly developed CRISPR-Cas tools and argue
on how their application could improve the currently
available technologies. Finally, we discuss how screening
diverse environments can lead to discovery of new Cas-
related variants to extend the repertoire of applications
and create novel production hosts.
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CRISPR-Cas9-based metabolic engineering of bacterial cell factories. Using Cas9 as counter-selection tool for traditional genome editing
processes such as recombineering or plasmid-based homologous recombination has led to efficient metabolic engineering towards a wide range
of products. Additionally, dCas9 can be used for CRISPRi to rapidly screen in silico predicted phenotypes prior to Cas9-based engineering.
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Bacterial metabolic engineering and CRISPR-
Cas technologies
Many chemicals such as terpenoids, alcohols, amino acids,
organic acids and antibiotics have high commercial value
in the pharmaceutical and nutritional industry, and as
fuels and building block chemicals. Most of these com-
pounds result from multi-step metabolic pathways and
are often tightly regulated in their natural genomic con-
text [22,23]. Model organisms, like E. coli, have well-
studied metabolisms, extensive and high-throughput
molecular toolboxes and detailed in silico metabolic mod-
els. Hence, the use of such organisms minimizes the
number of required engineering steps and maximizes
engineering efficiencies. Nevertheless, the demands for
engineering work remain high before efficient production
strains are constructed due to the complexity of the
metabolic pathways for many commercially interesting
products [2]. Moreover, model organisms are often sub-
optimal as production hosts and the use of alternative
organisms could benefit the production of many valuable
chemicals. Cas-based genome engineering and silencing
tools have enabled and accelerated complex metabolic
engineering and systems-level understanding of meta-
bolic pathways in a wide range of organisms [2,12,13,18]
(Figure 1).
CRISPR-Cas editing
Metabolic engineering strategies include plasmid-based
expression or, preferably, chromosomal integration of
heterologous metabolic pathways, and/or targeted
genome editing and adaptive evolution for flux redistri-
bution through native metabolic pathways (Table 1). In
their pioneering work, Li et al. [24] combined Cas9-
induced targeted DSBs with ss or ds l-RED recombi-
neering for the introduction of a heterologous b-carotene
biosynthetic pathway into the E. coli genome. They
further substituted the promoters and ribosome binding
sites (RBSs) from the native MEP pathway genes to
achieve different levels of overexpression of the corre-
sponding enzymes. Further engineering steps, including
numerous deletions and promoter/RBS substitutions of
central carbon metabolism genes, improved pyruvate and
glyceraldehyde-3P supply and lead to the construction of
a highly improved b-carotene producing strain [24].
This extensive study was possible only due to the devel-
opment of the Cas9-based tools, revealing their great
potential for efficient and diverse manipulation of geno-
mic DNA.
The Cas9-recombineering method was further exploited
with the development of the CRISPR-enabled trackable
genome engineering (CREATE) tool [25]. Application of
this tool in E. coli cells allowed their simultaneous trans-
formation with multiple libraries of plasmid-borne recom-
bination templates, each designed to introduce easily
trackable mutations at different genomic loci [25]. The
CREATE tool was employed to introduce multiple RBS
variations for each of the genes in a genomically inte-
grated isopropanol production pathway in E. coli, leading
to the time-efficient construction and testing of 1000
strains. The isopropanol titer of the best strain was 1.5-
fold higher compared to the initial integration strain, but
still lower compared to the plasmid-based overexpression
approach [26]. Cas9-based downregulation or deletion
of competing pathways in strains already overexpressing
heterologous pathways towards the desired product could
further improve titers. This has been proven successful
for many compounds, including n-butanol in E. coli [27]
and Clostridium saccharoperbutylacetonicum [28], isopropa-
nol-butanol-ethanol in Clostridium acetobutylicum [29], suc-
cinic acid in Synechococcus elongatus [30], g-amino-butyric
acid (GABA) in Corynebacterium glutamicum [31], and 5-
aminolevulinic acid in E. coli [32] (Table 1). However, the
use of natural producers can substantially reduce the
complexity of engineering steps towards production
and tolerance build-up. The tolerance of Streptomyces
species to antibiotics has been exploited for the produc-
tion of antibiotic and antitumor compounds simply by
Cas9-facilitated genomic integration of multiple biosyn-
thetic gene cluster (BGC) copies [33,34]. In C. glutamicum,
the natural proline production was enhanced 6.5-fold
through a codon saturation mutagenesis approach to
relieve product inhibition [35]. Noteworthy, this work
was performed using the Cas12a (formerly Cpf1) RNA-
guided endonuclease, making it the first application of a
non-Cas9-based CRISPR-Cas/recombineering genome
editing tool in bacteria for metabolic engineering pur-
poses (Table 1).
Finally, Cas9-based editing tools were successfully
employed for membrane engineering purposes in E.
coli. The b-carotene storage capacity of E. coli cell mem-
branes was increased by chromosomal integration of
heterologous membrane-bending protein genes using
plasmid-borne homologous recombination and Cas9-tar-
geting [36]. Furthermore, the Cas9-recombineering tool
proved efficient for the enhancement of the E. coli lipid
content by simultaneous chromosomal integration of a
heterologous fatty acid regulatory transcription factor
gene together with a delta9 desaturase and an acetyl-
CoA carboxylase gene [37] (Table 1).
CRISPRi
Next to the integration or deletion of genes and pathways,
an important metabolic engineering strategy is the fine-
tuning of gene expression. Whereas in eukaryotic systems
siRNA-techniques have since long enabled transcriptional
control, for prokaryotes such silencing tools have only
recently become available with the CRISPR interference
(CRISPRi) tool, which is based on dCas9: the catalytically
inactive variant of the Cas9 endonuclease [38]. This tool
can be used for complete or partial repression; repression
strength can be tuned by altering the position of the
selected protospacer within the targeted gene (Figure 2),
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Table 1
CRISPR-Cas-mediated metabolic engineering of bacteria for industrial products
Product Species Strategy Chromosomal
modifications made
using CRISPR-Cas-
editing
Ref.
Product pathway
overexpression
Chromosomal
deletions
Chromosomal
insertions
Chromosomal
substitutions
Terpenoids b-Carotene Escherichia coli Heterologous,
chromosomal
Competing pathways Product pathway Promoters, RBSs Knock-in crtE-crtB-
crtI-crtY + knock-out
ldhA, knock-in gps,
combinatorial
promoter/RBS
replacement of 9 MEP
pathway genes,
combinatorial
overexpressions and
deletions of 8 central
carbon metabolism
genes, knock-in 2nd
copies of selected MEP
and b-carotene
pathway genes
[24]
Native, plasmid;
Heterologous,
chromosomal
Product pathway Knock-in almgs under
control of various
regulatory parts (in a
b-carotene production
strain)
[36]
Alcohols Isopropanol Escherichia coli Heterologous,
chromosomal
Product pathway RBSs Knock-in and RBS
replacement of thl,
atoDA, adc, adh
[26]
n-Butanol Heterologous,
plasmid
50-UTR of
competing
pathway gene
Modification of gltA 50-
UTR for expression
reduction
[27]
Clostridium
saccharoper
butylacetonicum
Competing pathways Knock-out pta, buk [28]
Isopropanol-
butanol-ethanol
Clostridium
acetobutylicum
Heterologous
and native,
chromosomal
Product pathway Knock-in ctfAB, adc,
adh
[29]
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Table 1 (Continued )
Product Species Strategy Chromosomal
modifications made
using CRISPR-Cas-
editing
Ref.
Product pathway
overexpression
Chromosomal
deletions
Chromosomal
insertions
Chromosomal
substitutions
Amino acids L-Proline Corynebacterium
glutamicum
– Codons (to relieve
product inhibition)
Codon saturation
mutagenesis
g-glutamyl kinase by
CRISPR-Cpf1
[35]
g-Amino-butyric
acid (GABA)
Heterologous,
plasmid
Transporters,
degradation pathway
Knock-out Ncgl1221,
gabT, gabP and various
combinations thereof
[31]
5-Amino-levulinic
acid
Escherichia coli Heterologous,
plasmid
Competing pathways Promoter, codons
(to relieve product
inhibition)
coaA point mutation
(R106A), serA promoter
replacement and C-
terminal residues
deletion, knockout
sucCD, hemB
translational
downregulation by start
codon substitution
[32]
Org. acids Succinic acid Synechococcus
elongatus
Native,
chromosomal
Competing pathways Product pathway Knock-out glgc and
knock-in gltA-ppc
(under nitrogen
starvation conditions)
[30]
Antibiotics/
anti-tumor
Pristinamycin I (PI) Streptomyces
pristinaespiralis
Native,
chromosomal
Repressor,
competing pathway
Product pathway Knock-out snaEI,
snaE2 and papR3,
knock-in PI
biosynthetic gene
cluster
[33]
Pristinamycin II (PII) Native,
chromosomal
Product pathway Knock-in of artificial
bacteriophage
attachment/integration
(attB) sites in which the
biosynthetic pathway is
subsequently inserted
[34]
Chloramphenicol Streptomyces
coelicolor
Heterologous,
chromosomal
Product pathway
Anti-tumor compound
YM-216391
Heterologous,
chromosomal
Product pathway
Lipid
content
Fatty acids Escherichia coli Heterologous,
chromosomal
Competing pathways Product pathway Knock-in fadR, delta9
and acc (deletions
made previously)
[37]
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Table 2
CRISPRi-based metabolic engineering of bacteria for industrial products
Product Species Product pathway
overexpression
method
CRISPRi-based
repression ofa:
Genes targeted
by CRISPRi
Mb Ref.
Polyhydroxyalkanoates
(PHA)
P(3HB-co-4HB) with
enhanced
4HB content
Escherichia coli Heterologous,
plasmid
Competing pathways sad/gadB,
sucCD, sdhAB
+ [42]
Polyhydroxy-butyrate
(PHB)
Heterologous,
plasmid
Cell morphology ftsZ, mreB  [43]
PHB Heterologous,
plasmid
Product pathway phaC  [39]
3-Hydroxybutyrate/3-
hydroxyvalerate
(PHBV) and PHB
Halomonas sp. – Cell morphology
Product pathway
Competing pathways
ftsZ, prpC, gltA  [40]
Phytochemicals Zeaxanthin Escherichia coli Heterologous,
plasmid (+sensor
for dynamic
control) and
chromosomal
Cell morphology ftsZ, mreB, pbp,
rodZ
 [44]
Naringenin Heterologous,
plasmid
Competing pathways eno, adhE, mdh,
fabB, fabF, sucC,
fumC
+ [46]
Naringenin Heterologous,
plasmid
Competing pathways fadR, fumC,
sucABCD, scpC
+ [47]
Resveratrol Heterologous,
plasmid
Competing pathways fabD, fabH, fabB,
fabF, fabI
 [48]
Pinosylvin Heterologous,
plasmid
Competing pathways eno, adhE, fabB,
sucC, fumC, fabF
+ [49]
Anthocyanin Heterologous,
plasmid
Repressor of product
pathway
metJ  [50]
Fatty acids Medium chain fatty
acids (MCFAs)
Escherichia coli Heterologous and
native, plasmid
Competing pathways rdA, adhE, ldhA,
poxB, pta
 [51]
Terpenoids ()-a-Bisabolol,
isoprene,
lycopene
Escherichia coli Heterologous,
plasmid
Product pathway
Competing pathway:
biomass
mvaK1, mvaE,
ispA
 [41]
Mevalonate Heterologous,
plasmid
Competing pathway:
biomass
pyrF, oriC, dnaA  [53]
Amino acids L-Lysine, L-glutamate Corynebacterium
glutamicum
– Competing pathways pgi, pck, pyk  [45]
Alcohols Acetone-butanol-
ethanol
Clostridium
cellulovorans &
Clostridium
beijerinckii
Native, plasmid Competing pathways
(as well as knock-out)
putative
hydrogenase in C.
cellulovorans
 [54]
n-Butanol Klebsiella
pneumoniae
Heterologous,
plasmid
Competing pathways ilvB, ilvI, metA,
alaA
 [55]
Escherichia coli Heterologous,
plasmid
Competing pathways pta, frdA, ldhA,
adhE
+ [52]
Fatty alcohols Synechocystis sp. Heterologous,
plasmid
Competing pathways plsX, aar, ado,
plsC, lplat
+ [60]
Organic acids Succinate Synechococcus
elongatus
– Competing pathways
(under nitrogen
starvation conditions)
glgc, sdhA, sdhB  [56]
Lactate Synechococcus
sp.
– Competing pathway to
accumulate activator
metabolite
glnA  [59]
a See Figure 2 for a visualization of these strategies. Modifications other than CRISPRi are shown in brackets.
b M: multiplexing.
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Overview of CRISPRi-based metabolic engineering strategies to increase production of the target product (P). Abbreviations: C: carbon source; I:
intermediate metabolite; B: byproduct or biomass; P: target product; TI: toxic intermediate; R: repressor; M: morphology. See legend of Figure 1
for graphic legend. Arrows represent intracellular carbon flows and their thickness corresponds to the flow rate. Arrows with dashed outlines
represent merged pathways. (a) Repression of competing pathway that leads to byproduct or biomass formation with (i) indicating dCas9
targeting the promoter region, resulting in stronger repression than in (ii), where the coding region is targeted. (b) Repression of competing
pathway that leads to product consumption with (i) indicating dCas9 targeting the promoter region, resulting in stronger repression than in (ii),
where the coding region is targeted. (c) Repression of repressor of the target product pathway. (d) Repression of cell shape/morphology genes to
increase cell size and storage capacity for the target product. (e) Repression of the product pathway to change product composition or
properties. (f) Repression of the product pathway to prevent accumulation of toxic intermediates.
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or by employing an inducible promoter for the expression
of the dCas9 or the sgRNA module and altering the amount
of the corresponding inducer. This is crucial when target-
ing essential genes, competing pathways (which can also be
biomass-producing) or regulators for which a basal expres-
sion level is required (Figure 2a–d). It can also be used as a
quick alternative to the often laborious RBS/promoter-
engineering to tune production pathway activity to either
modulate amounts and properties of the target product
(Figure 2e) [39,40] or prevent accumulation of toxic inter-
mediates [41] (Figure 2f). Although CRISPRi does not lead
to the construction of stably genetically modified strains, it
is a powerful method for quick evaluation of the possible
effects of genetic modifications to the metabolism of a
microorganism, allowing to design genome editing
approaches and to gain insights into microbial metabolism
(Figure 1, Table 2).
Similar to CRISPR-Cas-based editing, model organisms
such as E. coli and C. glutamicum were the first organisms for
which CRISPRi-based metabolic engineering was applied
(Table 2). A heterologous polyhydroxyalkanoate (PHA)
biosynthesis pathway was introduced into E. coli for the
production of poly(3-hydroxybutyrate-co-4-hydroxybuty-
rate) [P(3HB-co-4HB)] [42]. The 4HB fraction of the
polymer was enhanced via CRISPRi-based downregulation
of multiple TCA cycle genes aiming to increase the supply
of the 4HB-precursor succinate semialdehyde [42]
(Figure 2e). Subsequent works in E. coli and in the natural
PHA-producer Halomonas focused on silencing cell mor-
phology genes to increase the storage capacity of the cells
for PHAs [40,43] (Figure 2d), as well as biosynthetic
pathway genes to control PHA content and chemical prop-
erties such as molecular weight and polydispersity [39,40]
(Figure 2d). Cell morphology engineering, through CRIS-
PRi-based repression of E. coli cell division and shape
genes, combined with expression of a heterologous produc-
tion pathway, was also used for the production of the
phytochemical zeaxanthin [44] (Table 2). Several other
studies used CRISPRi-based repression of competing path-
way or repressor genes for the enrichment of precursor pools
(Figure 2a,c), aiming at the enhancement of the natural
amino acid production by C. glutamicum [45] and the E. coli-
based heterologous production of various phytochemicals
including naringenin [46,47], resveratrol [48], pinosylvin
[49], anthocyanin [50], as well as medium chain fatty acids
(MCFAs) [51] and n-butanol [52] (Table 2). Additionally,
CRISPRi-based repression of essential genes was used to
minimize carbon loss towards biomass formation by decou-
pling growth and production [53] or flux balancing [41]
(Table 2). Notably, many of these studies employed mul-
tiplex silencing using an sgRNA approach, whereas Cress
et al. used a dual RNA (crRNA/tracrRNA) approach, devel-
oping a rapid CRISPR-array assembly method denoted as
CRISPathBrick [47]. This tool could facilitate multiplex
CRISPRi-based silencing in non-model organisms with
limited genetic toolboxes.
CRISPRi-based repression has already been used for
metabolic engineering purposes in non-model organisms
such as in Clostridium cellulovorans and Klebsiella pneumo-
niae for alcohol production [54,55], Synechococcus elongatus
for succinate production [56] (Table 2), as well as in
Clostridium acetobutylicum to relieve carbon catabolite
repression for sugar co-utilization [57]. The CRISPRi
tool is particularly useful in cyanobacteria, in which
genome editing is complicated and time consuming
due to slow growth and multiple chromosome copies
[56,58]. Furthermore, the ability to fine-tune expression
levels using CRISPRi was exploited in Synechococcus sp.,
where repression of nitrogen assimilation gene glnA was
shown to increase the pool of a-ketoglutarate [59]. A
moderate increase of this metabolite enhanced glycolytic
flux and lactate production, whereas a too large increase
resulted in a decrease in protein production [59]. CRIS-
PRi-based multiplex gene repression was established in
Synechocystis sp. [58] and subsequently used to determine
optimal gene repression combinations for fatty alcohol
production [60] (Table 2). As in all studies using CRISPRi
in cyanobacteria, dCas9 and sgRNAs were chromosomally
integrated into the genome. This resulted in stable
repression strains in the absence of selective pressure
for single sgRNAs, but the use of repetitive promoter
elements resulted in undesired recombination events
when multiplexing was attempted [60], highlighting
the potential advantage of using a dual RNA approach.
Finally, it was observed that a targeted gene with a very
distant transcription start site (TSS) from the start codon
could be efficiently repressed by CRISPRi only when
employing multiple sgRNAs targeting within the gene or
the preceding operon genes [58]. Hence, this study
revealed that the efficient application of the CRISPRi
tool is strongly connected with the precise identification
of TSS for the targeted genes.
Future perspectives
In prokaryotes, CRISPR-Cas based genome editing has
strongly increased engineering efficiencies by adding a
powerful counter-selection method to existing engineer-
ing systems or by enhancing recombination efficiencies
through induction of cellular DNA repair mechanisms
[12,20]. In model organism E. coli high-throughput tools
such as crMAGE [7] and CREATE [25] enabled mul-
tiplex engineering by combining the Cas9 and recombi-
neering tools. It is expected that these high-throughput
tools will be further developed into automated pipelines
for rapid industrial strain development, but the thorough
exploitation of their potential requires the additional
development of rapid and easy screening and read-out
systems.
CRISPR-Cas-based counter-selection tools have
increased editing efficiencies in many non-model organ-
isms. However, further improvement of these tools still
strongly depends on the development of basics, such as
CRISPR-Cas assisted bacterial metabolic engineering Mougiakos et al. 153
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well-characterized inducible promoters [61]. Tight con-
trol of the Cas9-expression would allow for efficient
integration of an employed homologous recombination
template prior to the counter-selection step. The use of
intrinsic Cas9-properties, such as temperature-sensitivity,
can substitute the requirement for inducible promoters in
organisms that can grow under conditions outside the
Cas9 activity range [62].
The use of alternative Class 2 CRISPR systems will
further extend the Cas-based engineering toolbox.
Recently, the Cpf1 (Cas12) RNA-guided DNA endonu-
cleases from the type V CRISPR-Cas systems of Franci-
sella novicida [35] and Acidaminococcus sp. [63] have been
repurposed for bacterial genome editing and silencing.
Cpf1 does not require a tracrRNA and can process its own
precursor crRNA via its intrinsic RNAse activity. Hence,
the use of Cpf1 for the development of a multiplex
engineering tool can prevent the issues encountered
when using Cas9 and multiple sgRNAs for multiplex
engineering [63]. The use of a Cpf1-recombineering tool
in C. glutamicum, which tolerates only very low levels of
Cas9 expression [31,35,64], resulted in screenable edit-
ing efficiencies [35], while a DNase-dead Cpf1 (ddCpf1)
variant was recently employed for multiplex silencing in
E. coli [63]. The newly discovered Class 2 Type VI system
Cas13 (C2c2) RNA-guided RNA-nuclease can be used for
silencing via the degradation of transcripts, or for tracking
of transcripts using fluorescent-coupled catalytically inac-
tive variants [65,66]. The RNA-guided RNA endonucle-
ase from the type VI CRISPR-Cas systems of Leptotrichia
shahii and Leptotrichia wadei have already been success-
fully repurposed for RNA interference in E. coli [67,68].
Furthermore, the repurposing of native CRISPR-Cas
systems for genome editing [69], has been proved effi-
cient and holds promise for organisms with low transfor-
mation efficiencies [70]. It is anticipated that the devel-
opment of easy and rapid characterization techniques
[71,72–74] will accelerate the exploitation of novel
CRISPR-Cas systems for the development of prokaryotic
engineering tools. These tools will further expand the
number of target sites, the range of easy-to-engineer
organisms and they will increase the engineering speed
by simultaneous usage of different Cas systems for
genome editing and plasmid curing [65,75], similar to
the recently developed EXIT-circuit approach that com-
bines Cas9-based editing and I-SceI-based plasmid curing
[76].
Screening natural resources for novel CRISPR-Cas sys-
tems will further expand the applications and range of
organisms and environments in which CRISPR-Cas-
based editing can be applied [77–79]. A recent example
of this approach is the identification of a thermostable
Cas9-orthologue in the genome of a Geobacillus thermo-
denitrificans strain isolated from a compost sample, which
was further characterized and employed to establish the
first Cas9-based engineering tool for thermophilic bacte-
ria [80]. The robustness of thermostable Cas9-based
tools can be further exploited for applications in extreme
environments, as was recently shown for another thermo-
stable Cas9-orthologue with prolonged life time in blood
plasma [81]. The discovery of novel Cas nucleases with
different properties, such as tolerance to alkaline or acidic
pH and high saline concentrations, would be possible by
screening selected environmental samples and metage-
nomic libraries. The characterization of these nucleases
could lead to the development of engineering tools with
wide applicability to biotechnologically relevant but cur-
rently unexploited extremophilic organisms.
Conclusions
Altogether, the developments in CRISPR-Cas-based bac-
terial genome engineering increase insight into metabo-
lism on a systems level and enable more rapid strain
engineering, which is crucial for the development of a
bio-based economy using microbial cell factories. Rapid
current developments and future applications, which will
further expand the range of organisms and applications of
CRISPR-Cas-based editing for metabolic engineering,
consist of fine-tuning of the tools, their adaptation to
different hosts, their extension into combinations with
other active components such as proteases, markers or
activators, as well as the discovery and development of
novel Cas-like systems.
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